A Founder Effect of c.257 + 2T > C Mutation in NCF2 Gene Underlies Severe Chronic Granulomatous Disease in Eleven Patients

J Clin Immunol. 2016 Aug;36(6):547-54. doi: 10.1007/s10875-016-0299-9. Epub 2016 May 25.

Abstract

Chronic granulomatous disease (CGD) is the prototypic functional neutrophil disorder caused by genetic defects in one of the five genes encoding the superoxide-generating nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase subunits of phagocytes. Mutations causing the most prevalent form of CGD in western populations are located in the X-linked-CYBB gene. The four remaining autosomal recessive (AR) forms collectively account for one-third of CGD cases. We investigated the clinical and molecular features of eleven patients with CGD from 6 consanguineous families, originating from contiguous regions in the west of Tunisia. The patients' clinical phenotype is characterized by a high incidence of mycobacterial infections. Five out of the eleven patients died despite treatment arguing in favor of a severe clinical form of CGD. These findings correlated with the absence of functional p67phox protein as well as the absence of residual reactive oxygen intermediates (ROI) production. Genetic analysis showed the presence, in all patients, of a unique mutation (c.257 + 2T > C) in NCF2 gene predicted to affect RNA splicing. Segregating analysis using nine polymorphic markers overlapping the NCF2 gene revealed a common haplotype spanning 4.1 Mb. The founder event responsible for this mutation was estimated to have arisen approximately 175 years ago. These findings will facilitate the implementation of preventive approaches through genetic counseling in affected consanguineous families.

Keywords: Chronic granulomatous disease; NCF2 gene; Tunisia; consanguinity; founder effect.

MeSH terms

  • Alleles*
  • Child
  • Child, Preschool
  • Consanguinity
  • DNA Mutational Analysis
  • Enzyme Activation
  • Female
  • Founder Effect*
  • Genetic Association Studies
  • Genetic Predisposition to Disease*
  • Granulomatous Disease, Chronic / diagnosis*
  • Granulomatous Disease, Chronic / genetics*
  • Granulomatous Disease, Chronic / metabolism
  • Haplotypes
  • Humans
  • Infant
  • Male
  • Mutation*
  • NADPH Oxidases / genetics*
  • NADPH Oxidases / metabolism
  • Neutrophils / immunology
  • Neutrophils / metabolism
  • Phenotype
  • Severity of Illness Index
  • Tunisia

Substances

  • NADPH Oxidases
  • NCF2 protein, human